



MAYNE PHARMA TO PRESENT AT ASX SMIDCAPS CONFERENCE

17 March 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces an upcoming presentation at the ASX SMIDcaps Conference in Sydney, Australia on Wednesday 25 March 2026.

Mayne Pharma's CEO Mr Aaron Gray will update investors on recent progress across Women's Health and Dermatology, and how the Company's recent DistributeRx launch is supporting improved access and a more direct pathway from prescription to patient, including Mayne Pharma's focus for the remainder of 2026.

The ASX SMIDcaps Conference will take place at:

The Library Auditorium, State Library of NSW, 1 Shakespeare Place, Sydney NSW.

Mayne Pharma's presentation will be at:

1.25pm AEDT on Wednesday, 25 March 2026

Investors who wish to attend the conference are required to register for the conference as an in-person participant or online at the following link:

<https://event.asx.com.au/asxsmidcapsconferencemarch2026>

Run as a hybrid, bi-annual conference, the ASX SMIDcaps Conference showcases the most promising ASX-listed small and mid-cap companies to a vast network of investors. The event brings investors and advisors up close and personal with emerging companies as they present their business vision, strategy and investment proposition.

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](https://www.maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia



About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.